Can a new pill boost the power of an existing leukemia treatment?
NCT ID NCT07761533
First seen Aug 12, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This trial is testing whether an experimental drug called PBSS1113, taken as a pill alongside the standard medicine azacitidine, can help people with acute myeloid leukemia (AML) or a related condition called myelodysplastic syndrome (MDS). The study includes adults who have either relapsed or not responded to prior treatment, or who are newly diagnosed but unable to receive intensive chemotherapy. The goal is to see if the combination is safe, tolerable, and effective at reducing or eliminating signs of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PBSS1113 (an experimental oral drug) combined with azacitidine (a standard chemotherapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with AML or higher-risk MDS, especially those who have relapsed or cannot tolerate intensive chemotherapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not prove effective or safe in larger studies. Side effects from the combination are possible and not yet fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Personalized dosing may improve stem cell transplant survival in blood cancer patients
- Massive AML trial aims to find best chemo and transplant protection for younger patients
- Could bone marrow from deceased donors cure blood cancers?